Heron Therapeutics Inc
NASDAQ:HRTX

  • LAST PRICE
    1.1400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.0900/ 100
  • Ask / Lots
    1.3000/ 5
  • Open / Previous Close
    --- / 1.1400
  • Day Range
    ---
  • 52 Week Range
    1.0400
    3.9300
  • Volume
    1

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 13, 2024

  • Nov 12, 2024

      Show headlines and story abstract

    • 7:56AM ET on Tuesday Nov 12, 2024 by MT Newswires
      Companies Mentioned: HRTX
      07:56 AM EST, 11/12/2024 (MT Newswires) -- ...

    • 7:56AM ET on Tuesday Nov 12, 2024 by MT Newswires
      Companies Mentioned: HRTX
      07:56 AM EST, 11/12/2024 (MT Newswires) -- ...

    • 7:55AM ET on Tuesday Nov 12, 2024 by PR Newswire
      Companies Mentioned: HRTX

      -- Reported positive YTD 2024 Adjusted EBITDA of $1.4 million

      -- Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million

      -- ZYNRELEF(R) (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch

    • 7:55AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: HRTX
      Gross Profit 23,352 13,226 75,084 37,591 --------- ---------- ---------- ---------- Operating expenses: Research and development 4,465 9,285 13,505 31,331 General and administrative 12,373 15,914 41,252 51,340 Sales and marketing 10,972 12,956 36,028 55,315 --------- ---------- ---------- ---------- Total operating expenses 27,810 38,155 90,785 137,986 --------- ---------- ---------- ---------- Loss from operations (4,458) (24,929) (15,701) (100,395) Other (expense) income, net (390) (79) (1,542) 560 --------- ---------- ---------- ---------- Net loss $ (4,848) $ (25,008) $ (17,243) $ (99,835) Basic and diluted net loss per share $ (0.03) $ (0.17) $ (0.11) $ (0.75) ========= ========== ========== ========== Weighted average common shares outstanding, basic and diluted 152,830 144,990 152,213 133,747 ========= ========== ========== ========== Heron Therapeutics, Inc. Consolidated Balance Sheets (in thousands) September 30, December 31, 2024 2023 ------------- ------------ (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 25,741 $ 28,677 Short-term investments 45,149 51,732 Accounts receivable, net 67,039 60,137 Inventory 45,950 42,110 Prepaid expenses and other current assets 11,308 6,118 ------------- ------------ Total current assets 195,187 188,774 Property and equipment, net 15,414 20,166 Right-of-use lease assets 3,469 5,438 Other assets 6,707 8,128 Total assets $ 220,777 $ 222,506 ============= ============ LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 10,188 $ 3,240 Accrued clinical and manufacturing liabilities 22,859 22,291 Accrued payroll and employee liabilities 8,531 9,224 Other accrued liabilities 40,717 41,855 Current lease liabilities 3,249 3,075 Total current liabilities 85,544 79,685 Non-current lease liabilities 522 2,800 Non-current notes payable, net 24,828 24,263 Non-current convertible notes payable, net 149,647 149,490 Other non-current liabilities 241 241 ------------- ------------ Total liabilities 260,782 256,479 ------------- ------------ Stockholders' deficit: Common stock 1,517 1,503 Additional paid-in capital 1,881,695 1,870,525 Accumulated other comprehensive (loss) income 40 13 Accumulated deficit (1,923,257) (1,906,014) ------------- ------------ Total stockholders' deficit (40,005) (33,973) ------------- ------------ Total liabilities and stockholders' deficit $ 220,777 $ 222,506 ============= ============

Peers Headlines